EyePoint Pharmaceuticals, Inc. (EYPT) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $376M · $4.48 · 52-week range $3.95–$19.11

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-08-18	Zaderej Karen L.	director	10,600	$4.93	$52,258	SEC Form 4
2026-03-16	Duker Jay S.	director, officer: President and CEO	1,500	$13.15	$19,724	SEC Form 4

Financial health

Altman Z-Score -7.75 · Piotroski F-Score 2/9 · Cash $306M · Debt $23M

ClearOcean signal read

ClearOcean's model currently scores EYPT as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — EYPT Form 4
How ClearOcean reads insider activity

Last updated August 31, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.